TG Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.45
- Today's High:
- $10.92
- Open Price:
- $10.51
- 52W Low:
- $4.86
- 52W High:
- $35.67
- Prev. Close:
- $10.62
- Volume:
- 2925621
Company Statistics
- Market Cap.:
- $1.61 billion
- Book Value:
- 0.287
- Revenue TTM:
- $24.05 million
- Operating Margin TTM:
- -701.36%
- Gross Profit TTM:
- $2.52 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -44.63%
- Return on Equity TTM:
- -207.27%
Company Profile
TG Therapeutics Inc had its IPO on 1995-12-14 under the ticker symbol TGTX.
The company operates in the Healthcare sector and Biotechnology industry. TG Therapeutics Inc has a staff strength of 244 employees.
Stock update
Shares of TG Therapeutics Inc opened at $10.51 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.45 - $10.92, and closed at $10.71.
This is a +0.85% increase from the previous day's closing price.
A total volume of 2,925,621 shares were traded at the close of the day’s session.
In the last one week, shares of TG Therapeutics Inc have increased by +0.94%.
TG Therapeutics Inc's Key Ratios
TG Therapeutics Inc has a market cap of $1.61 billion, indicating a price to book ratio of 10.8774 and a price to sales ratio of 249.2734.
In the last 12-months TG Therapeutics Inc’s revenue was $24.05 million with a gross profit of $2.52 million and an EBITDA of $-168442000. The EBITDA ratio measures TG Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, TG Therapeutics Inc’s operating margin was -701.36% while its return on assets stood at -44.63% with a return of equity of -207.27%.
In Q2, TG Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2606.1%.
TG Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TG Therapeutics Inc’s profitability.
TG Therapeutics Inc stock is trading at a EV to sales ratio of 198.8193 and a EV to EBITDA ratio of -4.3494. Its price to sales ratio in the trailing 12-months stood at 249.2734.
TG Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $-1433474000.00
- Total Liabilities
- $72.67 million
- Operating Cash Flow
- $30.50 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
TG Therapeutics Inc ended 2024 with $-1433474000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-1433474000.00 while shareholder equity stood at $-1613875000.00.
TG Therapeutics Inc ended 2024 with $229000.00 in deferred long-term liabilities, $72.67 million in other current liabilities, 151000.00 in common stock, $-1613875000.00 in retained earnings and $799000.00 in goodwill. Its cash balance stood at $97.01 million and cash and short-term investments were $144.91 million. The company’s total short-term debt was $1,512,000 while long-term debt stood at $97.70 million.
TG Therapeutics Inc’s total current assets stands at $144.91 million while long-term investments were $0.00 and short-term investments were $47.90 million. Its net receivables were $17.48 million compared to accounts payable of $69.59 million and inventory worth $30.23 million.
In 2024, TG Therapeutics Inc's operating cash flow was $30.50 million while its capital expenditure stood at $0.
Comparatively, TG Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.71
- 52-Week High
- $35.67
- 52-Week Low
- $4.86
- Analyst Target Price
- $28.94
TG Therapeutics Inc stock is currently trading at $10.71 per share. It touched a 52-week high of $35.67 and a 52-week low of $35.67. Analysts tracking the stock have a 12-month average target price of $28.94.
Its 50-day moving average was $15.15 and 200-day moving average was $17.62 The short ratio stood at 3.8 indicating a short percent outstanding of 0%.
Around 858.9% of the company’s stock are held by insiders while 6476.1% are held by institutions.
Frequently Asked Questions About TG Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.